Trial Profile
Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Untreated CLL/SLL The HiLOG Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Sep 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Methylprednisolone (Primary) ; Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms HiLO; HiLOG
- 21 Aug 2023 Planned End Date changed from 4 Aug 2023 to 4 Aug 2024.
- 27 Jun 2023 Planned End Date changed from 1 Jul 2023 to 4 Aug 2023.
- 15 Aug 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.